Responding to the updated draft guidance from NICE to not recommend Perjeta (pertuzumab) for routine NHS use after surgery for early HER2-positive...

17 August 2018

Responding to news that health officials are investigating concerns that adults who should have been invited for breast and bowel cancer screening...

11 August 2018

Discussing the news that NHS trusts are being encouraged to move away from the breast cancer drug Herceptin to use a biologically similar medicine,...

31 July 2018

Responding to the publication of NICE’s updated guidance for early and locally advanced breast cancer, Samia al Qadhi, Chief Executive of Breast...

18 July 2018

Responding to the news that flight attendants are more likely to develop several forms of cancer than the average person, Addie Mitchell, Clinical...

26 June 2018

Responding to new evidence from the Institute of Cancer Research suggesting that higher BMIs in young women reduce their risk of breast cancer,...

21 June 2018

Responding to a new review by the Royal College of Surgeons and the Association of Breast Surgery revealing that older women are less likely to...

19 June 2018

Responding to a new report revealing hundreds of women with breast cancer are being denied or rushed into surgery as policies restrict breast...

18 June 2018

Responding to the announcement by NICE to not recommend Perjeta (pertuzumab) for routine NHS use after surgery for early HER2-positive breast cancer...

15 June 2018